Genomic Vision Société Anonyme
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glas… Read more
Genomic Vision Société Anonyme (G09) - Net Assets
Latest net assets as of June 2023: €-2.77 Million EUR
Based on the latest financial reports, Genomic Vision Société Anonyme (G09) has net assets worth €-2.77 Million EUR as of June 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.96 Million) and total liabilities (€6.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-2.77 Million |
| % of Total Assets | -70.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | -130.9% |
| 10-Year Change | N/A |
| Growth Volatility | 707.43 |
Genomic Vision Société Anonyme - Net Assets Trend (2013–2022)
This chart illustrates how Genomic Vision Société Anonyme's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genomic Vision Société Anonyme (2013–2022)
The table below shows the annual net assets of Genomic Vision Société Anonyme from 2013 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | €-1.29 Million | -141.97% |
| 2021-12-31 | €3.07 Million | -1.76% |
| 2020-12-31 | €3.12 Million | -3.19% |
| 2019-12-31 | €3.23 Million | -22.58% |
| 2018-12-31 | €4.17 Million | +10.94% |
| 2017-12-31 | €3.76 Million | -62.56% |
| 2016-12-31 | €10.04 Million | -45.41% |
| 2015-12-31 | €18.38 Million | -19.00% |
| 2014-12-31 | €22.70 Million | +2211.10% |
| 2013-12-31 | €982.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genomic Vision Société Anonyme's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 328300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €5.50 Million | % |
| Total Equity | €-1.29 Million | 100.00% |
Genomic Vision Société Anonyme Competitors by Market Cap
The table below lists competitors of Genomic Vision Société Anonyme ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Giant Motorsports Inc
PINK:BZRD
|
$712.16K |
|
SYROS PHARMAC.NEW DL-001
F:0S90
|
$712.24K |
|
Emmaus Life Sciences Inc
OTCQB:EMMA
|
$712.27K |
|
Uniinfo Telecom Services Limited
NSE:UNIINFO
|
$712.35K |
|
CL8 Holdings Ltd
AU:CL8
|
$711.19K |
|
Taiton Resources Ltd
AU:T88
|
$710.97K |
|
Hopium SAS
PA:ALHPI
|
$710.81K |
|
Societe Parisienne d’apports En Capital SPAC SA
PA:MHM
|
$710.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomic Vision Société Anonyme's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 3,069,000 to -1,288,000, a change of -4,357,000 (-142.0%).
- Net loss of 6,790,000 reduced equity.
- Other factors increased equity by 2,433,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-6.79 Million | -527.17% |
| Other Changes | €2.43 Million | +188.9% |
| Total Change | €- | -141.97% |
Book Value vs Market Value Analysis
This analysis compares Genomic Vision Société Anonyme's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €0.67 | €1065.75 | x |
| 2018-12-31 | €0.27 | €1065.75 | x |
| 2019-12-31 | €0.07 | €1065.75 | x |
| 2020-12-31 | €0.06 | €1065.75 | x |
| 2021-12-31 | €0.05 | €1065.75 | x |
| 2022-12-31 | €-0.01 | €1065.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomic Vision Société Anonyme utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -458.78%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-110.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -108.86% | -26.63% | 0.69x | 5.91x | €-1.17 Million |
| 2014 | -9.50% | -44.44% | 0.18x | 1.17x | €-4.43 Million |
| 2015 | -23.60% | -101.50% | 0.19x | 1.19x | €-6.18 Million |
| 2016 | -85.83% | -283.79% | 0.23x | 1.32x | €-9.62 Million |
| 2017 | -241.44% | -253.95% | 0.43x | 2.20x | €-9.45 Million |
| 2018 | -165.50% | -362.29% | 0.22x | 2.09x | €-7.31 Million |
| 2019 | -142.80% | -205.81% | 0.40x | 1.74x | €-4.93 Million |
| 2020 | -165.72% | -399.15% | 0.18x | 2.34x | €-5.49 Million |
| 2021 | -162.85% | -353.72% | 0.21x | 2.21x | €-5.30 Million |
| 2022 | 0.00% | -458.78% | 0.30x | 0.00x | €-6.66 Million |
Industry Comparison
This section compares Genomic Vision Société Anonyme's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,334,087,496
- Average return on equity (ROE) among peers: -14.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genomic Vision Société Anonyme (G09) | €-2.77 Million | -108.86% | N/A | $711.54K |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |